259 related articles for article (PubMed ID: 24725477)
1. Skin cancer in organ transplant recipients: more than the immune system.
Wheless L; Jacks S; Mooneyham Potter KA; Leach BC; Cook J
J Am Acad Dermatol; 2014 Aug; 71(2):359-65. PubMed ID: 24725477
[TBL] [Abstract][Full Text] [Related]
2. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients.
Gluck M; Hodak E; Davidovici B
Dermatol Ther; 2022 Aug; 35(8):e15649. PubMed ID: 35716099
[TBL] [Abstract][Full Text] [Related]
4. Overview on non-melanoma skin cancers in solid organ transplant recipients.
Forchetti G; Suppa M; Del Marmol V
G Ital Dermatol Venereol; 2014 Aug; 149(4):383-7. PubMed ID: 25068224
[TBL] [Abstract][Full Text] [Related]
5. Nonmelanoma Skin Cancers After Kidney Transplant: Our 15 Years of Experience With Mammalian Target of Rapamycin Inhibitors.
Okut G; Alp A; Tatar E; Simsek C; Tugmen C; Uslu A
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):236-239. PubMed ID: 28260475
[TBL] [Abstract][Full Text] [Related]
6. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
7. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients.
Funk-Debleds P; Ducroux E; Guillaud O; Ursic-Bedoya J; Decullier E; Vallin M; Euvrard S; Pageaux GP; Boillot O; Dumortier J
J Am Acad Dermatol; 2018 Jul; 79(1):84-91. PubMed ID: 29307647
[TBL] [Abstract][Full Text] [Related]
8. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair.
Kuschal C; Thoms KM; Schubert S; Schäfer A; Boeckmann L; Schön MP; Emmert S
Exp Dermatol; 2012 Jan; 21(1):2-6. PubMed ID: 22151386
[TBL] [Abstract][Full Text] [Related]
9. Risk prediction tools for keratinocyte carcinoma after solid organ transplantation: a review of the literature.
Lowenstein SE; Garrett G; Toland AE; Jambusaria-Pahlajani A; Asgari MM; Green A; Engels EA; Arron ST;
Br J Dermatol; 2017 Nov; 177(5):1202-1207. PubMed ID: 28952162
[TBL] [Abstract][Full Text] [Related]
10. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids.
Kreher MA; Noland MMB; Konda S; Longo MI; Valdes-Rodriguez R
J Am Acad Dermatol; 2023 Mar; 88(3):521-530. PubMed ID: 36460257
[TBL] [Abstract][Full Text] [Related]
11. Management of non-melanoma skin cancer in solid organ transplant recipients.
Specchio F; Saraceno R; Chimenti S; Nistico S
Int J Immunopathol Pharmacol; 2014; 27(1):21-4. PubMed ID: 24674675
[TBL] [Abstract][Full Text] [Related]
12. Declining incidence of keratinocyte carcinoma in organ transplant recipients.
Menzies S; O'Leary E; Callaghan G; Galligan M; Deady S; Gadallah B; Lenane P; Lally A; Houlihan DD; Morris PG; Sexton DJ; McCormick PA; Egan JJ; O'Neill JP; Conlon PJ; Moloney FJ
Br J Dermatol; 2019 Nov; 181(5):983-991. PubMed ID: 31049932
[TBL] [Abstract][Full Text] [Related]
13. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management.
Tessari G; Girolomoni G
Dermatol Surg; 2012 Oct; 38(10):1622-30. PubMed ID: 22805312
[TBL] [Abstract][Full Text] [Related]
14. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
15. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ
Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
[TBL] [Abstract][Full Text] [Related]
16. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
17. Nonmelanoma skin cancer in organ transplant recipients: increase without delay after transplant and subsequent acceleration.
Muehleisen B; Pazhenkottil A; French LE; Hofbauer GF
JAMA Dermatol; 2013 May; 149(5):618-20. PubMed ID: 23677099
[No Abstract] [Full Text] [Related]
18. Skin cancer in organ transplant recipients--where do we stand today?
Ulrich C; Kanitakis J; Stockfleth E; Euvrard S
Am J Transplant; 2008 Nov; 8(11):2192-8. PubMed ID: 18782290
[TBL] [Abstract][Full Text] [Related]
19. Organ transplantation and skin cancer: basic problems and new perspectives.
Hofbauer GF; Bouwes Bavinck JN; Euvrard S
Exp Dermatol; 2010 Jun; 19(6):473-82. PubMed ID: 20482618
[TBL] [Abstract][Full Text] [Related]
20. Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.
Harradine KA; Ridd K; Saunier EF; Clermont FF; Perez-Losada J; Moore DH; Epstein EH; Bastian BC; Akhurst RJ
Clin Cancer Res; 2009 Aug; 15(16):5101-7. PubMed ID: 19671862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
